摘要
目的:探讨文拉法辛联合拉莫三嗪治疗难治性抑郁症的辅助效果及安全性。方法:将60例难治性抑郁症患者随机分为两组:对照组30例,单用文拉法辛(150～225 mg/d)治疗;治疗组30例,在采用文拉法辛(150～225 mg/d)治疗的同时,联合应用拉莫三嗪(100～300 mg/d)。两组持续治疗观察期均为12周。于入组前、入组后第6周和第12周末分别应用汉密尔顿抑郁量表、Qids-C16抑郁症状学记录量表及副反应量表进行评定。结果:①治疗第6,12周末,两组间HAMD、Qids-C16评分的差异有统计学意义(P<0.05或P<0.01)。②治疗组的总有效率为96.67%,对照组的总有效率为50%,两组间的差异有统计学意义(P<0.01)。③治疗组患者中10例出现不良反应,占33.3%;对照组为9例,占30.0%,两组患者的副反应均较轻微。结论:文拉法辛联合拉莫三嗪治疗难治性抑郁症的疗效优于单用文拉法辛,安全性较好,可用于临床治疗。
Objective： To explore the effects and safety of lamotrigine amalgamation of venlafaxine on the treatment-resistant depression.Methods： All 60 patients with the treatment-resistant depression we are randomly assigned to the two groups： lamotrigine（100~300 mg/d） plus venlafaxine or venlafaxine alone They were estimated with Hamilton Depression Scale（HAMD）,Qids-C16,and Treatment Emergent Symptom（TESS） at baseline and every six or twelve weeks subsequently.The study lasted for 12 weeks.Results：①There were differences on the scores of HAMD and Qids-C16 between the two groups at the endpoint of treatment（P0.05或P0.01）.②In the amalgamation treatment group,96.67% responded,while 50% responded in mono-therapy group venlafaxine.amalgamation treatment group produced greater improvement than mono-therapy group（P0.01）.③ In amalgamation treatment group 33.3% of patients showed different but mild side effects,in comparison with 30% in venlafaxine group（P0.05）.Conclusion：Lamotrigine may be more useful and safety adjunct to venlafaxine than using venlafaxine alone in treatment-resistant depression.It may become one of the ways to choice in the clinical treatment.
出处
《天津药学》
2012年第2期9-11,共3页
Tianjin Pharmacy
关键词
难治性抑郁症
文拉法辛
拉莫三嗪
treatment-resistant depression
venlafaxine
amalgamation
